Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
March 30 2021 - 6:34AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of March 2021
Commission
File Number 001-15170
GlaxoSmithKline plc
(Translation
of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ____
30 March 2021, London, U.K.
GlaxoSmithKline plc (GSK)
GSK publishes respiratory product sales reporting
changes
|
Respiratory and HIV categories for reported sales to be
updated
To reflect the different stages of the product life-cycle of
certain respiratory products and to ensure consistency of reporting
for the sales of products with similar levels of strategic focus,
the reporting of Relvar/Breo
Ellipta along with the
smaller Incruse
Ellipta and Arnuity
Ellipta product sales will
with effect from the first quarter of 2021 be reported under the
"Established Respiratory" section of our "Established
Pharmaceuticals" category. Product sales
of Trelegy
Ellipta, Nucala and Anoro
Ellipta will continue to
be reported within the "Respiratory" category.
In addition, the reporting of sales of Epzicom/Kivexa and Selzentry will
going forward be incorporated into the "Other HIV" line within the
"HIV category".
The revised Pharmaceutical turnover tables below set out the
revised format for reporting Pharmaceutical product sales that will
be used from the first quarter 2021 results, in respect of the 2020
Pharmaceutical product sales.
An Excel version of this data is available
on www.gsk.com.
|
|
(GSK) - one of the world's
leading research-based pharmaceutical and healthcare companies - is
committed to improving the quality of human life by enabling people
to do more, feel better and live longer. For further
information please visit www.gsk.com
|
|
|
|
|
Analyst/Investor enquiries:
|
James Dodwell
|
+44 (0) 20 8047 2406
|
(London)
|
|
Jeff McLaughlin
|
+1 215 751 7002
|
(Philadelphia)
|
|
Frannie DeFranco
|
+1 215 751 4855
|
(Philadelphia)
|
Brand names
Brand names appearing in italics throughout this document are
trademarks of GSK or associated companies or used under licence by
the Group.
This Announcement does not constitute statutory accounts of the
Group within the meaning of sections 434(3) and 435(3) of the
Companies Act 2006. The information for 2020 has been derived
from the full Group accounts published in the Annual Report
2020.
CER growth
In order to illustrate underlying performance, it is the Group's
practice to discuss its results in terms of constant exchange rate
(CER) growth. This represents growth calculated as if the exchange
rates used to determine the results of overseas companies in
Sterling had remained unchanged from those used in the comparative
period.
|
|
Registered
in England & Wales:
No. 3888792
|
|
Registered
Office:
980 Great West
Road
Brentford,
Middlesex
TW8 9GS
|
|
Revised format for reporting Pharmaceuticals product
sales
The revised format for the reporting of Pharmaceutical product
sales applied to the 2020 Pharmaceutical sales is as
follows:
Pharmaceuticals turnover - year ended 31 December 2020
|
Total
|
US
|
Europe
|
International
|
|
-------------------------------------
|
-------------------------------------
|
-------------------------------------
|
-------------------------------------
|
|
|
Growth
|
|
Growth
|
|
Growth
|
|
Growth
|
|
|
-----------------------
|
|
-----------------------
|
|
-----------------------
|
|
-----------------------
|
|
£m
|
£%
|
CER%
|
£m
|
£%
|
CER%
|
£m
|
£%
|
CER%
|
£m
|
£%
|
CER%
|
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Respiratory
|
2,360
|
31
|
32
|
1,486
|
28
|
30
|
548
|
28
|
27
|
326
|
53
|
56
|
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
Anoro Ellipta
|
547
|
6
|
8
|
327
|
1
|
2
|
142
|
18
|
17
|
78
|
11
|
17
|
Trelegy Ellipta
|
819
|
58
|
59
|
561
|
47
|
48
|
168
|
65
|
65
|
90
|
>100
|
>100
|
Nucala
|
994
|
29
|
30
|
598
|
32
|
33
|
238
|
16
|
15
|
158
|
45
|
46
|
|
|
|
|
|
|
|
|
|
|
|
|
|
HIV
|
4,876
|
-
|
1
|
3,005
|
-
|
1
|
1,213
|
5
|
4
|
658
|
(5)
|
(1)
|
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
Dolutegravir products
|
4,702
|
1
|
2
|
2,941
|
-
|
1
|
1,163
|
7
|
6
|
598
|
(2)
|
3
|
Tivicay
|
1,527
|
(8)
|
(7)
|
871
|
(11)
|
(10)
|
368
|
(7)
|
(8)
|
288
|
(1)
|
5
|
Triumeq
|
2,306
|
(10)
|
(9)
|
1,454
|
(10)
|
(9)
|
568
|
(9)
|
(10)
|
284
|
(9)
|
(6)
|
Juluca
|
495
|
35
|
36
|
387
|
28
|
29
|
97
|
73
|
71
|
11
|
57
|
71
|
Dovato
|
374
|
>100
|
>100
|
229
|
>100
|
>100
|
130
|
>100
|
>100
|
15
|
>100
|
>100
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Rukobia
|
11
|
-
|
-
|
11
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cabenuva
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Other
|
163
|
(26)
|
(25)
|
53
|
(20)
|
(18)
|
50
|
(29)
|
(27)
|
60
|
(29)
|
(28)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Immuno-Inflammation and
Other Specialty
|
727
|
19
|
20
|
612
|
14
|
16
|
56
|
22
|
20
|
59
|
84
|
91
|
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
Benlysta
|
719
|
17
|
19
|
612
|
14
|
16
|
56
|
22
|
20
|
51
|
59
|
66
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Oncology
|
372
|
62
|
62
|
231
|
72
|
74
|
136
|
42
|
40
|
5
|
-
|
-
|
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
Zejula
|
339
|
48
|
48
|
206
|
54
|
55
|
128
|
35
|
33
|
5
|
-
|
-
|
Blenrep
|
33
|
-
|
-
|
25
|
-
|
-
|
8
|
-
|
-
|
-
|
-
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
New and Specialty Pharmaceuticals
|
8,335
|
11
|
12
|
5,334
|
10
|
12
|
1,953
|
13
|
12
|
1,048
|
12
|
16
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Established
Pharmaceuticals
|
8,721
|
(13)
|
(12)
|
2,117
|
(18)
|
(17)
|
2,151
|
(10)
|
(11)
|
4,453
|
(12)
|
(9)
|
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
Established
Respiratory
|
4,640
|
(10)
|
(9)
|
1,676
|
(16)
|
(15)
|
1,134
|
(2)
|
(3)
|
1,830
|
(9)
|
(6)
|
Arnuity Ellipta
|
45
|
(6)
|
(6)
|
37
|
(10)
|
(7)
|
-
|
-
|
-
|
8
|
14
|
-
|
Avamys/Veramyst
|
297
|
(8)
|
(6)
|
-
|
-
|
-
|
66
|
(4)
|
(4)
|
231
|
(10)
|
(7)
|
Flixotide/Flovent
|
419
|
(33)
|
(32)
|
183
|
(50)
|
(50)
|
80
|
(9)
|
(10)
|
156
|
(10)
|
(5)
|
Incruse Ellipta
|
220
|
(16)
|
(15)
|
117
|
(27)
|
(27)
|
74
|
1
|
1
|
29
|
4
|
7
|
Relvar/Breo Ellipta
|
1,124
|
16
|
17
|
474
|
24
|
25
|
322
|
14
|
13
|
328
|
6
|
9
|
Seretide/Advair
|
1,535
|
(11)
|
(10)
|
434
|
(14)
|
(13)
|
449
|
(11)
|
(11)
|
652
|
(10)
|
(7)
|
Ventolin
|
785
|
(16)
|
(14)
|
430
|
(21)
|
(20)
|
116
|
(3)
|
(4)
|
239
|
(12)
|
(7)
|
Other Respiratory
|
215
|
(23)
|
(23)
|
1
|
>100
|
>100
|
27
|
(4)
|
-
|
187
|
(25)
|
(26)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Dermatology
|
425
|
(4)
|
(1)
|
1
|
(67)
|
(67)
|
140
|
(12)
|
(13)
|
284
|
-
|
6
|
Augmentin
|
490
|
(19)
|
(15)
|
-
|
-
|
-
|
145
|
(16)
|
(16)
|
345
|
(20)
|
(15)
|
Avodart
|
466
|
(19)
|
(17)
|
5
|
25
|
25
|
158
|
(24)
|
(25)
|
303
|
(16)
|
(13)
|
Imigran/Imitrex
|
118
|
(14)
|
(14)
|
42
|
(29)
|
(29)
|
51
|
(2)
|
(4)
|
25
|
(7)
|
(4)
|
Lamictal
|
537
|
(5)
|
(4)
|
269
|
(5)
|
(5)
|
120
|
7
|
6
|
148
|
(13)
|
(9)
|
Seroxat/Paxil
|
146
|
(9)
|
(6)
|
-
|
-
|
-
|
37
|
-
|
(3)
|
109
|
(11)
|
(7)
|
Valtrex
|
103
|
(4)
|
(2)
|
15
|
7
|
7
|
32
|
3
|
-
|
56
|
(10)
|
(5)
|
Other
|
1,796
|
(21)
|
(20)
|
109
|
(48)
|
(47)
|
334
|
(28)
|
(28)
|
1,353
|
(16)
|
(14)
|
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
Pharmaceuticals
|
17,056
|
(3)
|
(1)
|
7,451
|
1
|
2
|
4,104
|
(1)
|
(1)
|
5,501
|
(9)
|
(5)
|
|
--------
|
--------
|
--------
|
--------
|
----------
|
--------
|
--------
|
---------
|
--------
|
--------
|
---------
|
--------
|
|
Pharmaceuticals turnover - three months ended 31 December
2020
|
|
Total
|
US
|
Europe
|
International
|
|
-------------------------------------
|
-------------------------------------
|
-------------------------------------
|
-------------------------------------
|
|
|
Growth
|
|
Growth
|
|
Growth
|
|
Growth
|
|
|
-----------------------
|
|
-----------------------
|
|
-----------------------
|
|
-----------------------
|
|
£m
|
£%
|
CER%
|
£m
|
£%
|
CER%
|
£m
|
£%
|
CER%
|
£m
|
£%
|
CER%
|
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Respiratory
|
681
|
28
|
29
|
435
|
25
|
27
|
150
|
23
|
19
|
96
|
60
|
63
|
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
Anoro Ellipta
|
151
|
7
|
8
|
90
|
(1)
|
1
|
39
|
18
|
15
|
22
|
29
|
29
|
Trelegy Ellipta
|
238
|
38
|
40
|
161
|
28
|
30
|
48
|
45
|
42
|
29
|
>100
|
>100
|
Nucala
|
292
|
34
|
34
|
184
|
39
|
42
|
63
|
13
|
7
|
45
|
50
|
53
|
|
|
|
|
|
|
|
|
|
|
|
|
|
HIV
|
1,268
|
1
|
2
|
805
|
3
|
5
|
327
|
10
|
6
|
136
|
(24)
|
(21)
|
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
Dolutegravir products
|
1,225
|
1
|
2
|
786
|
2
|
4
|
315
|
13
|
8
|
124
|
(23)
|
(19)
|
Tivicay
|
365
|
(14)
|
(13)
|
229
|
(6)
|
(4)
|
88
|
(12)
|
(17)
|
48
|
(41)
|
(35)
|
Triumeq
|
580
|
(9)
|
(9)
|
370
|
(9)
|
(7)
|
143
|
(7)
|
(10)
|
67
|
(13)
|
(13)
|
Juluca
|
139
|
25
|
25
|
108
|
21
|
22
|
28
|
47
|
37
|
3
|
-
|
33
|
Dovato
|
141
|
>100
|
>100
|
79
|
>100
|
>100
|
56
|
>100
|
>100
|
6
|
>100
|
>100
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Rukobia
|
8
|
-
|
-
|
8
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cabenuva
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Other
|
35
|
(29)
|
(20)
|
11
|
(21)
|
-
|
12
|
(33)
|
(22)
|
12
|
(29)
|
(35)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Immuno-Inflammation and
Other Specialty
|
206
|
21
|
24
|
175
|
18
|
21
|
15
|
25
|
17
|
16
|
60
|
70
|
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
Benlysta
|
205
|
21
|
23
|
175
|
18
|
21
|
15
|
25
|
17
|
15
|
50
|
60
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Oncology
|
115
|
74
|
74
|
75
|
>100
|
>100
|
37
|
28
|
21
|
3
|
-
|
-
|
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
Zejula
|
89
|
35
|
35
|
54
|
46
|
51
|
32
|
10
|
3
|
3
|
-
|
-
|
Blenrep
|
25
|
-
|
-
|
20
|
-
|
-
|
5
|
-
|
-
|
-
|
-
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
New and Specialty Pharmaceuticals
|
2,270
|
12
|
13
|
1,490
|
13
|
16
|
529
|
15
|
11
|
251
|
1
|
5
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Established
Pharmaceuticals
|
2,096
|
(17)
|
(16)
|
484
|
(25)
|
(23)
|
528
|
(10)
|
(13)
|
1,084
|
(17)
|
(15)
|
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
Established
Respiratory
|
1,092
|
(18)
|
(17)
|
373
|
(27)
|
(26)
|
278
|
(3)
|
(7)
|
441
|
(16)
|
(14)
|
Arnuity Ellipta
|
14
|
(7)
|
(13)
|
11
|
(15)
|
(8)
|
-
|
-
|
-
|
3
|
50
|
(50)
|
Avamys/Veramyst
|
70
|
(3)
|
(1)
|
-
|
-
|
-
|
15
|
-
|
-
|
55
|
(7)
|
(5)
|
Flixotide/Flovent
|
87
|
(53)
|
(52)
|
34
|
(70)
|
(69)
|
20
|
(9)
|
(18)
|
33
|
(33)
|
(29)
|
Incruse Ellipta
|
48
|
(38)
|
(38)
|
21
|
(60)
|
(58)
|
19
|
6
|
-
|
8
|
14
|
14
|
Relvar/Breo Ellipta
|
274
|
2
|
2
|
107
|
-
|
1
|
84
|
14
|
11
|
83
|
(6)
|
(3)
|
Seretide/Advair
|
351
|
(15)
|
(15)
|
73
|
(30)
|
(28)
|
105
|
(12)
|
(16)
|
173
|
(9)
|
(7)
|
Ventolin
|
211
|
(7)
|
(5)
|
125
|
1
|
3
|
29
|
(6)
|
(13)
|
57
|
(20)
|
(15)
|
Other Respiratory
|
37
|
(45)
|
(48)
|
2
|
>100
|
>100
|
6
|
(33)
|
(11)
|
29
|
(50)
|
(53)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Dermatology
|
109
|
(3)
|
-
|
-
|
-
|
-
|
36
|
(10)
|
(12)
|
73
|
1
|
7
|
Augmentin
|
115
|
(27)
|
(24)
|
-
|
-
|
-
|
37
|
(21)
|
(26)
|
78
|
(30)
|
(23)
|
Avodart
|
96
|
(31)
|
(31)
|
1
|
>100
|
>100
|
34
|
(29)
|
(31)
|
61
|
(34)
|
(33)
|
Imigran/Imitrex
|
27
|
(23)
|
(26)
|
6
|
(60)
|
(60)
|
14
|
8
|
-
|
7
|
-
|
-
|
Lamictal
|
140
|
(3)
|
(3)
|
73
|
-
|
-
|
30
|
7
|
4
|
37
|
(16)
|
(11)
|
Seroxat/Paxil
|
36
|
(5)
|
(3)
|
-
|
-
|
-
|
10
|
11
|
-
|
26
|
(10)
|
(3)
|
Valtrex
|
26
|
(4)
|
(4)
|
4
|
-
|
-
|
8
|
-
|
(13)
|
14
|
(7)
|
-
|
Other
|
455
|
(18)
|
(17)
|
27
|
(27)
|
(16)
|
81
|
(25)
|
(25)
|
347
|
(15)
|
(14)
|
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
Pharmaceuticals
|
4,366
|
(4)
|
(3)
|
1,974
|
1
|
3
|
1,057
|
1
|
(3)
|
1,335
|
(14)
|
(12)
|
|
--------
|
--------
|
--------
|
--------
|
----------
|
--------
|
--------
|
---------
|
--------
|
--------
|
---------
|
--------
|
Pharmaceuticals turnover - nine months ended 30 September
2020
|
|
Total
|
US
|
Europe
|
International
|
|
-------------------------------------
|
-------------------------------------
|
-------------------------------------
|
-------------------------------------
|
|
|
Growth
|
|
Growth
|
|
Growth
|
|
Growth
|
|
|
-----------------------
|
|
-----------------------
|
|
-----------------------
|
|
-----------------------
|
|
£m
|
£%
|
CER%
|
£m
|
£%
|
CER%
|
£m
|
£%
|
CER%
|
£m
|
£%
|
CER%
|
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Respiratory
|
1,679
|
32
|
33
|
1,051
|
30
|
31
|
398
|
30
|
31
|
230
|
50
|
53
|
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
Anoro Ellipta
|
396
|
6
|
8
|
237
|
2
|
2
|
103
|
18
|
18
|
56
|
6
|
13
|
Trelegy Ellipta
|
581
|
68
|
69
|
400
|
56
|
57
|
120
|
74
|
75
|
61
|
>100
|
>100
|
Nucala
|
702
|
28
|
28
|
414
|
29
|
30
|
175
|
17
|
17
|
113
|
43
|
43
|
|
|
|
|
|
|
|
|
|
|
|
|
|
HIV
|
3,608
|
-
|
1
|
2,200
|
(1)
|
-
|
886
|
3
|
3
|
522
|
1
|
6
|
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
Dolutegravir products
|
3,477
|
2
|
3
|
2,155
|
(1)
|
-
|
848
|
5
|
5
|
474
|
6
|
11
|
Tivicay
|
1,162
|
(6)
|
(5)
|
642
|
(12)
|
(12)
|
280
|
(5)
|
(5)
|
240
|
15
|
21
|
Triumeq
|
1,726
|
(10)
|
(9)
|
1,084
|
(10)
|
(9)
|
425
|
(10)
|
(10)
|
217
|
(8)
|
(4)
|
Juluca
|
356
|
40
|
41
|
279
|
30
|
31
|
69
|
86
|
89
|
8
|
100
|
100
|
Dovato
|
233
|
>100
|
>100
|
150
|
>100
|
>100
|
74
|
>100
|
>100
|
9
|
>100
|
>100
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Rukobia
|
3
|
-
|
-
|
3
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cabenuva
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Other
|
128
|
(26)
|
(26)
|
42
|
(19)
|
(23)
|
38
|
(27)
|
(29)
|
48
|
(29)
|
(26)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Immuno-Inflammation and
Other Specialty
|
521
|
18
|
19
|
437
|
13
|
14
|
41
|
21
|
21
|
43
|
95
|
100
|
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
Benlysta
|
514
|
16
|
17
|
437
|
13
|
14
|
41
|
21
|
21
|
36
|
64
|
68
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Oncology
|
257
|
57
|
57
|
156
|
61
|
62
|
99
|
48
|
48
|
2
|
-
|
-
|
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
Zejula
|
250
|
53
|
53
|
152
|
57
|
57
|
96
|
45
|
45
|
2
|
-
|
-
|
Blenrep
|
8
|
-
|
-
|
5
|
-
|
-
|
3
|
-
|
-
|
-
|
-
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
New and Specialty Pharmaceuticals
|
6,065
|
11
|
12
|
3,844
|
9
|
10
|
1,424
|
12
|
13
|
797
|
16
|
20
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Established
Pharmaceuticals
|
6,625
|
(12)
|
(10)
|
1,633
|
(15)
|
(15)
|
1,623
|
(10)
|
(10)
|
3,369
|
(11)
|
(7)
|
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
Established
Respiratory
|
3,548
|
(8)
|
(6)
|
1,303
|
(12)
|
(12)
|
856
|
(2)
|
(2)
|
1,389
|
(7)
|
(4)
|
Arnuity Ellipta
|
31
|
(6)
|
(3)
|
26
|
(7)
|
(7)
|
-
|
-
|
-
|
5
|
-
|
20
|
Avamys/Veramyst
|
227
|
(10)
|
(7)
|
-
|
-
|
-
|
51
|
(6)
|
(6)
|
176
|
(11)
|
(8)
|
Flixotide/Flovent
|
332
|
(25)
|
(23)
|
149
|
(41)
|
(41)
|
60
|
(9)
|
(8)
|
123
|
(1)
|
4
|
Incruse Ellipta
|
172
|
(7)
|
(6)
|
96
|
(12)
|
(12)
|
55
|
-
|
2
|
21
|
-
|
5
|
Relvar/Breo Ellipta
|
850
|
21
|
22
|
367
|
34
|
35
|
238
|
14
|
14
|
245
|
11
|
14
|
Seretide/Advair
|
1,184
|
(10)
|
(8)
|
361
|
(9)
|
(9)
|
344
|
(10)
|
(10)
|
479
|
(10)
|
(7)
|
Ventolin
|
574
|
(19)
|
(17)
|
305
|
(28)
|
(27)
|
87
|
(2)
|
(1)
|
182
|
(9)
|
(3)
|
Other Respiratory
|
178
|
(16)
|
(16)
|
(1)
|
-
|
-
|
21
|
11
|
5
|
158
|
(18)
|
(18)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Dermatology
|
316
|
(5)
|
(2)
|
1
|
(67)
|
(67)
|
104
|
(13)
|
(13)
|
211
|
-
|
6
|
Augmentin
|
375
|
(16)
|
(12)
|
-
|
-
|
-
|
108
|
(14)
|
(13)
|
267
|
(16)
|
(12)
|
Avodart
|
370
|
(15)
|
(12)
|
4
|
-
|
-
|
124
|
(23)
|
(23)
|
242
|
(10)
|
(6)
|
Imigran/Imitrex
|
91
|
(12)
|
(11)
|
36
|
(18)
|
(18)
|
37
|
(5)
|
(5)
|
18
|
(10)
|
(5)
|
Lamictal
|
397
|
(6)
|
(4)
|
196
|
(7)
|
(6)
|
90
|
7
|
7
|
111
|
(12)
|
(8)
|
Seroxat/Paxil
|
110
|
(10)
|
(7)
|
-
|
-
|
-
|
27
|
(4)
|
(4)
|
83
|
(12)
|
(9)
|
Valtrex
|
77
|
(4)
|
(1)
|
11
|
10
|
10
|
24
|
4
|
4
|
42
|
(11)
|
(6)
|
Other
|
1,341
|
(23)
|
(21)
|
82
|
(52)
|
(53)
|
253
|
(29)
|
(29)
|
1,006
|
(16)
|
(13)
|
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
Pharmaceuticals
|
12,690
|
(2)
|
(1)
|
5,477
|
1
|
1
|
3,047
|
(1)
|
(1)
|
4,166
|
(7)
|
(3)
|
|
--------
|
--------
|
--------
|
--------
|
----------
|
--------
|
--------
|
---------
|
--------
|
--------
|
---------
|
--------
|
Pharmaceuticals turnover - three months ended 30 September
2020
|
|
Total
|
US
|
Europe
|
International
|
|
-------------------------------------
|
-------------------------------------
|
-------------------------------------
|
-------------------------------------
|
|
|
Growth
|
|
Growth
|
|
Growth
|
|
Growth
|
|
|
-----------------------
|
|
-----------------------
|
|
-----------------------
|
|
-----------------------
|
|
£m
|
£%
|
CER%
|
£m
|
£%
|
CER%
|
£m
|
£%
|
CER%
|
£m
|
£%
|
CER%
|
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Respiratory
|
585
|
21
|
26
|
361
|
14
|
20
|
136
|
23
|
23
|
88
|
57
|
64
|
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
Anoro Ellipta
|
140
|
(2)
|
3
|
86
|
(9)
|
(4)
|
35
|
17
|
13
|
19
|
-
|
21
|
Trelegy Ellipta
|
194
|
40
|
45
|
126
|
20
|
29
|
42
|
50
|
54
|
26
|
>100
|
>100
|
Nucala
|
251
|
24
|
29
|
149
|
25
|
32
|
59
|
11
|
11
|
43
|
39
|
45
|
|
|
|
|
|
|
|
|
|
|
|
|
|
HIV
|
1,216
|
(4)
|
-
|
755
|
(5)
|
-
|
296
|
1
|
1
|
165
|
(7)
|
1
|
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
Dolutegravir products
|
1,176
|
(3)
|
1
|
739
|
(5)
|
-
|
284
|
3
|
4
|
153
|
(2)
|
5
|
Tivicay
|
377
|
(15)
|
(10)
|
220
|
(18)
|
(13)
|
87
|
(15)
|
(14)
|
70
|
(1)
|
7
|
Triumeq
|
577
|
(11)
|
(8)
|
368
|
(11)
|
(6)
|
135
|
(12)
|
(13)
|
74
|
(11)
|
(5)
|
Juluca
|
123
|
22
|
28
|
95
|
14
|
20
|
24
|
50
|
56
|
4
|
>100
|
100
|
Dovato
|
99
|
>100
|
>100
|
56
|
>100
|
>100
|
38
|
>100
|
>100
|
5
|
>100
|
>100
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Rukobia
|
3
|
-
|
-
|
3
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cabenuva
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Other
|
37
|
(34)
|
(32)
|
13
|
(24)
|
(24)
|
12
|
(33)
|
(39)
|
12
|
(43)
|
(33)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Immuno-Inflammation and
Other Specialty
|
193
|
13
|
18
|
158
|
5
|
11
|
15
|
25
|
25
|
20
|
>100
|
>100
|
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
Benlysta
|
186
|
8
|
13
|
158
|
5
|
11
|
15
|
25
|
25
|
13
|
30
|
40
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Oncology
|
99
|
55
|
58
|
61
|
61
|
68
|
36
|
35
|
35
|
2
|
>100
|
>100
|
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
Zejula
|
92
|
44
|
47
|
57
|
50
|
55
|
33
|
27
|
27
|
2
|
>100
|
>100
|
Blenrep
|
8
|
-
|
-
|
5
|
-
|
-
|
3
|
-
|
-
|
-
|
-
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
New and Specialty Pharmaceuticals
|
2,093
|
5
|
10
|
1,335
|
2
|
8
|
483
|
9
|
9
|
275
|
14
|
21
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Established
Pharmaceuticals
|
2,099
|
(17)
|
(13)
|
583
|
(13)
|
(9)
|
491
|
(18)
|
(18)
|
1,025
|
(20)
|
(12)
|
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
Established
Respiratory
|
1,118
|
(11)
|
(6)
|
471
|
(8)
|
(3)
|
253
|
(8)
|
(8)
|
394
|
(17)
|
(9)
|
Arnuity Ellipta
|
14
|
17
|
33
|
13
|
30
|
30
|
-
|
-
|
-
|
1
|
(50)
|
50
|
Avamys/Veramyst
|
56
|
(15)
|
(8)
|
-
|
-
|
-
|
13
|
(13)
|
(13)
|
43
|
(16)
|
(6)
|
Flixotide/Flovent
|
92
|
(46)
|
(42)
|
45
|
(59)
|
(57)
|
15
|
(17)
|
(17)
|
32
|
(26)
|
(14)
|
Incruse Ellipta
|
56
|
(7)
|
(2)
|
33
|
(3)
|
3
|
16
|
(11)
|
(6)
|
7
|
(13)
|
(12)
|
Relvar/Breo Ellipta
|
323
|
30
|
34
|
169
|
64
|
70
|
73
|
3
|
1
|
81
|
8
|
15
|
Seretide/Advair
|
368
|
(12)
|
(8)
|
112
|
(4)
|
(1)
|
104
|
(14)
|
(14)
|
152
|
(16)
|
(8)
|
Ventolin
|
177
|
(23)
|
(18)
|
100
|
(26)
|
(22)
|
25
|
(7)
|
(4)
|
52
|
(24)
|
(15)
|
Other Respiratory
|
32
|
(40)
|
(28)
|
(1)
|
-
|
-
|
7
|
75
|
50
|
26
|
(46)
|
(38)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Dermatology
|
110
|
(7)
|
(1)
|
-
|
-
|
-
|
36
|
(10)
|
(13)
|
74
|
(5)
|
5
|
Augmentin
|
106
|
(30)
|
(24)
|
-
|
-
|
-
|
30
|
(21)
|
(21)
|
76
|
(33)
|
(25)
|
Avodart
|
95
|
(37)
|
(30)
|
1
|
(50)
|
(50)
|
36
|
(29)
|
(29)
|
58
|
(40)
|
(30)
|
Imigran/Imitrex
|
30
|
(17)
|
(14)
|
11
|
(27)
|
(27)
|
12
|
(8)
|
(8)
|
7
|
(13)
|
-
|
Lamictal
|
125
|
(15)
|
(10)
|
61
|
(18)
|
(12)
|
30
|
(3)
|
(3)
|
34
|
(19)
|
(10)
|
Seroxat/Paxil
|
38
|
(10)
|
(2)
|
-
|
-
|
-
|
9
|
(10)
|
(10)
|
29
|
(9)
|
-
|
Valtrex
|
24
|
(14)
|
(7)
|
4
|
-
|
-
|
8
|
(11)
|
(11)
|
12
|
(20)
|
(7)
|
Other
|
453
|
(26)
|
(22)
|
35
|
(44)
|
(46)
|
77
|
(41)
|
(40)
|
341
|
(18)
|
(13)
|
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
Pharmaceuticals
|
4,192
|
(7)
|
(3)
|
1,918
|
(3)
|
2
|
974
|
(6)
|
(6)
|
1,300
|
(14)
|
(7)
|
|
--------
|
--------
|
--------
|
--------
|
----------
|
--------
|
--------
|
---------
|
--------
|
--------
|
---------
|
--------
|
Pharmaceuticals turnover - six months ended 30 June
2020
|
|
Total
|
US
|
Europe
|
International
|
|
-------------------------------------
|
-------------------------------------
|
-------------------------------------
|
-------------------------------------
|
|
|
Growth
|
|
Growth
|
|
Growth
|
|
Growth
|
|
|
-----------------------
|
|
-----------------------
|
|
-----------------------
|
|
-----------------------
|
|
£m
|
£%
|
CER%
|
£m
|
£%
|
CER%
|
£m
|
£%
|
CER%
|
£m
|
£%
|
CER%
|
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Respiratory
|
1,094
|
40
|
38
|
690
|
40
|
37
|
262
|
34
|
35
|
142
|
46
|
46
|
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
Anoro Ellipta
|
256
|
11
|
10
|
151
|
9
|
6
|
68
|
19
|
21
|
37
|
9
|
9
|
Trelegy Ellipta
|
387
|
87
|
85
|
274
|
81
|
77
|
78
|
90
|
90
|
35
|
>100
|
>100
|
Nucala
|
451
|
30
|
28
|
265
|
31
|
29
|
116
|
20
|
21
|
70
|
46
|
42
|
|
|
|
|
|
|
|
|
|
|
|
|
|
HIV
|
2,392
|
3
|
2
|
1,445
|
1
|
(1)
|
590
|
4
|
4
|
357
|
6
|
9
|
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
Dolutegravir products
|
2,301
|
4
|
3
|
1,416
|
2
|
-
|
564
|
6
|
6
|
321
|
10
|
14
|
Tivicay
|
785
|
(1)
|
(2)
|
422
|
(9)
|
(11)
|
193
|
-
|
-
|
170
|
24
|
28
|
Triumeq
|
1,149
|
(9)
|
(10)
|
716
|
(9)
|
(11)
|
290
|
(9)
|
(9)
|
143
|
(6)
|
(3)
|
Juluca
|
233
|
51
|
49
|
184
|
40
|
38
|
45
|
>100
|
>100
|
4
|
100
|
100
|
Dovato
|
134
|
>100
|
>100
|
94
|
>100
|
>100
|
36
|
-
|
-
|
4
|
>100
|
>100
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Rukobia
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cabenuva
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Other
|
91
|
(22)
|
(23)
|
29
|
(17)
|
(23)
|
26
|
(24)
|
(24)
|
36
|
(23)
|
(23)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Immuno-Inflammation and
Other Specialty
|
328
|
21
|
19
|
279
|
18
|
16
|
26
|
18
|
18
|
23
|
77
|
77
|
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
Benlysta
|
328
|
21
|
19
|
279
|
18
|
16
|
26
|
18
|
18
|
23
|
92
|
92
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Oncology
|
158
|
58
|
57
|
95
|
61
|
58
|
63
|
54
|
54
|
-
|
-
|
-
|
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
Zejula
|
158
|
60
|
58
|
95
|
61
|
58
|
63
|
57
|
57
|
-
|
-
|
-
|
Blenrep
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
New and Specialty Pharmaceuticals
|
3,972
|
14
|
13
|
2,509
|
13
|
11
|
941
|
14
|
15
|
522
|
16
|
19
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Established
Pharmaceuticals
|
4,526
|
(9)
|
(9)
|
1,050
|
(17)
|
(18)
|
1,132
|
(7)
|
(6)
|
2,344
|
(6)
|
(5)
|
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
Established
Respiratory
|
2,430
|
(6)
|
(6)
|
832
|
(15)
|
(16)
|
603
|
-
|
1
|
995
|
(3)
|
(1)
|
Arnuity Ellipta
|
17
|
(19)
|
(24)
|
13
|
(28)
|
(28)
|
-
|
-
|
-
|
4
|
33
|
-
|
Avamys/Veramyst
|
171
|
(8)
|
(7)
|
-
|
-
|
-
|
38
|
(3)
|
(3)
|
133
|
(10)
|
(8)
|
Flixotide/Flovent
|
240
|
(12)
|
(12)
|
104
|
(27)
|
(29)
|
45
|
(6)
|
(4)
|
91
|
12
|
14
|
Incruse Ellipta
|
116
|
(7)
|
(8)
|
63
|
(16)
|
(19)
|
39
|
5
|
5
|
14
|
8
|
15
|
Relvar/Breo Ellipta
|
527
|
16
|
16
|
198
|
16
|
14
|
165
|
20
|
20
|
164
|
13
|
14
|
Seretide/Advair
|
816
|
(9)
|
(9)
|
249
|
(11)
|
(12)
|
240
|
(8)
|
(8)
|
327
|
(8)
|
(6)
|
Ventolin
|
397
|
(17)
|
(17)
|
205
|
(29)
|
(30)
|
62
|
-
|
-
|
130
|
(2)
|
2
|
Other Respiratory
|
146
|
(8)
|
(11)
|
-
|
-
|
-
|
14
|
(7)
|
(7)
|
132
|
(9)
|
(12)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Dermatology
|
206
|
(4)
|
(2)
|
1
|
(67)
|
(67)
|
68
|
(14)
|
(13)
|
137
|
3
|
6
|
Augmentin
|
269
|
(8)
|
(6)
|
-
|
-
|
-
|
78
|
(10)
|
(9)
|
191
|
(7)
|
(5)
|
Avodart
|
275
|
(3)
|
(3)
|
3
|
50
|
50
|
88
|
(19)
|
(19)
|
184
|
6
|
7
|
Imigran/Imitrex
|
61
|
(9)
|
(9)
|
25
|
(14)
|
(14)
|
25
|
(4)
|
(4)
|
11
|
(8)
|
(8)
|
Lamictal
|
272
|
(1)
|
(1)
|
135
|
(1)
|
(3)
|
60
|
13
|
13
|
77
|
(8)
|
(7)
|
Seroxat/Paxil
|
72
|
(10)
|
(10)
|
-
|
-
|
-
|
18
|
-
|
-
|
54
|
(13)
|
(13)
|
Valtrex
|
53
|
2
|
2
|
7
|
17
|
17
|
16
|
14
|
14
|
30
|
(6)
|
(6)
|
Other
|
888
|
(21)
|
(20)
|
47
|
(56)
|
(57)
|
176
|
(23)
|
(22)
|
665
|
(15)
|
(14)
|
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
Pharmaceuticals
|
8,498
|
-
|
-
|
3,559
|
3
|
1
|
2,073
|
2
|
2
|
2,866
|
(3)
|
(2)
|
|
--------
|
--------
|
--------
|
--------
|
----------
|
--------
|
--------
|
---------
|
--------
|
--------
|
---------
|
--------
|
Pharmaceuticals turnover - three months ended 30 June
2020
|
|
Total
|
US
|
Europe
|
International
|
|
-------------------------------------
|
-------------------------------------
|
-------------------------------------
|
-------------------------------------
|
|
|
Growth
|
|
Growth
|
|
Growth
|
|
Growth
|
|
|
-----------------------
|
|
-----------------------
|
|
-----------------------
|
|
-----------------------
|
|
£m
|
£%
|
CER%
|
£m
|
£%
|
CER%
|
£m
|
£%
|
CER%
|
£m
|
£%
|
CER%
|
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Respiratory
|
574
|
30
|
27
|
378
|
34
|
30
|
122
|
17
|
18
|
74
|
32
|
27
|
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
Anoro Ellipta
|
139
|
9
|
6
|
88
|
9
|
5
|
32
|
7
|
10
|
19
|
12
|
6
|
Trelegy Ellipta
|
194
|
62
|
58
|
140
|
65
|
60
|
36
|
64
|
59
|
18
|
38
|
46
|
Nucala
|
241
|
24
|
21
|
150
|
28
|
26
|
54
|
4
|
6
|
37
|
42
|
31
|
|
|
|
|
|
|
|
|
|
|
|
|
|
HIV
|
1,185
|
(2)
|
(3)
|
740
|
1
|
(2)
|
270
|
(7)
|
(7)
|
175
|
(5)
|
(2)
|
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
Dolutegravir products
|
1,140
|
(1)
|
(2)
|
725
|
1
|
(2)
|
259
|
(4)
|
(5)
|
156
|
-
|
4
|
Tivicay
|
373
|
(9)
|
(10)
|
208
|
(14)
|
(16)
|
87
|
(12)
|
(14)
|
78
|
10
|
15
|
Triumeq
|
586
|
(9)
|
(11)
|
378
|
(6)
|
(9)
|
134
|
(16)
|
(16)
|
74
|
(12)
|
(10)
|
Juluca
|
113
|
35
|
33
|
90
|
29
|
27
|
21
|
62
|
62
|
2
|
100
|
>100
|
Dovato
|
68
|
>100
|
>100
|
49
|
>100
|
>100
|
17
|
-
|
-
|
2
|
>100
|
>100
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Rukobia
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cabenuva
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Other
|
45
|
(27)
|
(32)
|
15
|
(6)
|
(19)
|
11
|
(39)
|
(39)
|
19
|
(32)
|
(36)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Immuno-Inflammation and
Other Specialty
|
177
|
17
|
15
|
153
|
16
|
14
|
12
|
9
|
-
|
12
|
50
|
50
|
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
Benlysta
|
177
|
18
|
15
|
153
|
16
|
14
|
12
|
9
|
-
|
12
|
71
|
71
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Oncology
|
77
|
35
|
33
|
47
|
42
|
39
|
30
|
25
|
21
|
-
|
-
|
-
|
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
Zejula
|
77
|
35
|
32
|
47
|
42
|
39
|
30
|
25
|
21
|
-
|
-
|
-
|
Blenrep
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
New and Specialty Pharmaceuticals
|
2,013
|
8
|
6
|
1,318
|
11
|
9
|
434
|
2
|
1
|
261
|
5
|
6
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Established
Pharmaceuticals
|
2,089
|
(15)
|
(15)
|
483
|
(19)
|
(21)
|
497
|
(18)
|
(19)
|
1,109
|
(11)
|
(9)
|
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
Established
Respiratory
|
1,114
|
(9)
|
(9)
|
377
|
(15)
|
(17)
|
276
|
(7)
|
(8)
|
461
|
(4)
|
(2)
|
Arnuity Ellipta
|
8
|
(43)
|
(50)
|
6
|
(50)
|
(50)
|
-
|
-
|
-
|
2
|
-
|
(50)
|
Avamys/Veramyst
|
62
|
(13)
|
(10)
|
-
|
-
|
-
|
19
|
(5)
|
(10)
|
43
|
(16)
|
(10)
|
Flixotide/Flovent
|
117
|
(7)
|
(7)
|
54
|
(17)
|
(18)
|
17
|
(23)
|
(18)
|
46
|
18
|
18
|
Incruse Ellipta
|
59
|
4
|
2
|
33
|
6
|
-
|
19
|
-
|
-
|
7
|
-
|
14
|
Relvar/Breo Ellipta
|
242
|
2
|
2
|
83
|
(11)
|
(12)
|
78
|
11
|
9
|
81
|
8
|
12
|
Seretide/Advair
|
421
|
2
|
2
|
143
|
36
|
34
|
113
|
(12)
|
(13)
|
165
|
(7)
|
(6)
|
Ventolin
|
144
|
(39)
|
(39)
|
58
|
(59)
|
(60)
|
24
|
(17)
|
(21)
|
62
|
(6)
|
(2)
|
Other Respiratory
|
61
|
(10)
|
(16)
|
-
|
-
|
-
|
6
|
(25)
|
(12)
|
55
|
(10)
|
(16)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Dermatology
|
95
|
(11)
|
(9)
|
1
|
-
|
-
|
30
|
(27)
|
(24)
|
64
|
(2)
|
-
|
Augmentin
|
100
|
(25)
|
(23)
|
-
|
-
|
-
|
21
|
(45)
|
(45)
|
79
|
(17)
|
(17)
|
Avodart
|
134
|
(5)
|
(6)
|
2
|
100
|
100
|
39
|
(26)
|
(28)
|
93
|
7
|
7
|
Imigran/Imitrex
|
27
|
(25)
|
(28)
|
10
|
(41)
|
(41)
|
12
|
(8)
|
(15)
|
5
|
(17)
|
(17)
|
Lamictal
|
135
|
(5)
|
(6)
|
66
|
(8)
|
(10)
|
28
|
-
|
(4)
|
41
|
(2)
|
(2)
|
Seroxat/Paxil
|
36
|
(10)
|
(10)
|
-
|
-
|
-
|
8
|
(11)
|
(11)
|
28
|
(10)
|
(10)
|
Valtrex
|
25
|
-
|
-
|
3
|
>100
|
>100
|
7
|
-
|
-
|
15
|
(12)
|
(12)
|
Other
|
423
|
(30)
|
(29)
|
24
|
(61)
|
(62)
|
76
|
(37)
|
(36)
|
323
|
(23)
|
(22)
|
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
Pharmaceuticals
|
4,102
|
(5)
|
(5)
|
1,801
|
1
|
(1)
|
931
|
(10)
|
(11)
|
1,370
|
(8)
|
(7)
|
|
--------
|
--------
|
--------
|
--------
|
----------
|
--------
|
--------
|
---------
|
--------
|
--------
|
---------
|
--------
|
Pharmaceuticals turnover - three months ended 31 March
2020
|
|
Total
|
US
|
Europe
|
International
|
|
-------------------------------------
|
-------------------------------------
|
-------------------------------------
|
-------------------------------------
|
|
|
Growth
|
|
Growth
|
|
Growth
|
|
Growth
|
|
|
-----------------------
|
|
-----------------------
|
|
-----------------------
|
|
-----------------------
|
|
£m
|
£%
|
CER%
|
£m
|
£%
|
CER%
|
£m
|
£%
|
CER%
|
£m
|
£%
|
CER%
|
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Respiratory
|
520
|
52
|
52
|
312
|
49
|
47
|
140
|
54
|
55
|
68
|
66
|
73
|
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
Anoro Ellipta
|
117
|
15
|
16
|
63
|
9
|
9
|
36
|
33
|
33
|
18
|
6
|
12
|
Trelegy Ellipta
|
193
|
>100
|
>100
|
134
|
>100
|
>100
|
42
|
>100
|
>100
|
17
|
>100
|
>100
|
Nucala
|
210
|
38
|
38
|
115
|
35
|
33
|
62
|
38
|
38
|
33
|
50
|
55
|
|
|
|
|
|
|
|
|
|
|
|
|
|
HIV
|
1,207
|
8
|
8
|
705
|
2
|
1
|
320
|
15
|
17
|
182
|
18
|
21
|
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
Dolutegravir products
|
1,161
|
9
|
9
|
691
|
3
|
2
|
305
|
16
|
18
|
165
|
22
|
25
|
Tivicay
|
412
|
8
|
8
|
214
|
(4)
|
(5)
|
106
|
13
|
15
|
92
|
39
|
42
|
Triumeq
|
563
|
(8)
|
(8)
|
338
|
(12)
|
(13)
|
156
|
(3)
|
(1)
|
69
|
1
|
4
|
Juluca
|
120
|
71
|
69
|
94
|
54
|
51
|
24
|
>100
|
>100
|
2
|
100
|
100
|
Dovato
|
66
|
-
|
-
|
45
|
-
|
-
|
19
|
-
|
-
|
2
|
-
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Rukobia
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cabenuva
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Other
|
46
|
(15)
|
(13)
|
14
|
(26)
|
(26)
|
15
|
(6)
|
(6)
|
17
|
(11)
|
(5)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Immuno-Inflammation and
Other Specialty
|
151
|
25
|
24
|
126
|
20
|
18
|
14
|
27
|
36
|
11
|
>100
|
>100
|
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
Benlysta
|
151
|
25
|
24
|
126
|
20
|
18
|
14
|
27
|
36
|
11
|
>100
|
>100
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Oncology
|
81
|
88
|
88
|
48
|
85
|
81
|
33
|
94
|
100
|
-
|
-
|
-
|
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
Zejula
|
81
|
93
|
93
|
48
|
85
|
81
|
33
|
>100
|
>100
|
-
|
-
|
-
|
Blenrep
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
New and Specialty Pharmaceuticals
|
1,959
|
20
|
20
|
1,191
|
16
|
14
|
507
|
28
|
29
|
261
|
31
|
35
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Established
Pharmaceuticals
|
2,437
|
(4)
|
(3)
|
567
|
(14)
|
(15)
|
635
|
5
|
6
|
1,235
|
(2)
|
(1)
|
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
Established
Respiratory
|
1,316
|
(4)
|
(4)
|
455
|
(14)
|
(15)
|
327
|
8
|
10
|
534
|
(1)
|
(1)
|
Arnuity Ellipta
|
9
|
29
|
29
|
7
|
17
|
17
|
-
|
-
|
-
|
2
|
100
|
100
|
Avamys/Veramyst
|
109
|
(5)
|
(5)
|
-
|
-
|
-
|
19
|
-
|
5
|
90
|
(6)
|
(7)
|
Flixotide/Flovent
|
123
|
(16)
|
(16)
|
50
|
(36)
|
(37)
|
28
|
8
|
8
|
45
|
7
|
10
|
Incruse Ellipta
|
57
|
(16)
|
(16)
|
30
|
(32)
|
(32)
|
20
|
11
|
11
|
7
|
17
|
17
|
Relvar/Breo Ellipta
|
285
|
33
|
32
|
115
|
47
|
45
|
87
|
30
|
33
|
83
|
19
|
16
|
Seretide/Advair
|
395
|
(19)
|
(18)
|
106
|
(40)
|
(40)
|
127
|
(5)
|
(3)
|
162
|
(8)
|
(7)
|
Ventolin
|
253
|
3
|
4
|
147
|
1
|
(1)
|
38
|
15
|
18
|
68
|
3
|
6
|
Other Respiratory
|
85
|
(7)
|
(8)
|
-
|
-
|
-
|
8
|
14
|
-
|
77
|
(8)
|
(8)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Dermatology
|
111
|
3
|
6
|
-
|
-
|
-
|
38
|
-
|
-
|
73
|
7
|
12
|
Augmentin
|
169
|
6
|
8
|
-
|
-
|
-
|
57
|
16
|
18
|
112
|
1
|
3
|
Avodart
|
141
|
(1)
|
-
|
1
|
-
|
-
|
49
|
(13)
|
(11)
|
91
|
6
|
7
|
Imigran/Imitrex
|
34
|
10
|
13
|
15
|
25
|
25
|
13
|
-
|
8
|
6
|
-
|
-
|
Lamictal
|
137
|
4
|
5
|
69
|
6
|
5
|
32
|
28
|
32
|
36
|
(14)
|
(12)
|
Seroxat/Paxil
|
36
|
(10)
|
(10)
|
-
|
-
|
-
|
10
|
11
|
11
|
26
|
(16)
|
(16)
|
Valtrex
|
28
|
4
|
4
|
4
|
(20)
|
(20)
|
9
|
29
|
29
|
15
|
-
|
-
|
Other
|
465
|
(10)
|
(9)
|
23
|
(51)
|
(51)
|
100
|
(6)
|
(7)
|
342
|
(6)
|
(4)
|
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
Pharmaceuticals
|
4,396
|
6
|
6
|
1,758
|
4
|
3
|
1,142
|
14
|
15
|
1,496
|
2
|
4
|
|
--------
|
--------
|
--------
|
--------
|
----------
|
--------
|
--------
|
---------
|
--------
|
--------
|
---------
|
--------
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
GlaxoSmithKline plc
|
|
(Registrant)
|
|
|
Date: March
30, 2021
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
Victoria Whyte
|
|
Authorised
Signatory for and on
|
|
behalf
of GlaxoSmithKline plc
|
GSK (NYSE:GSK)
Historical Stock Chart
From Sep 2024 to Oct 2024
GSK (NYSE:GSK)
Historical Stock Chart
From Oct 2023 to Oct 2024